Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR EXPRESSION
EGFR EXPRESSION - Associated Disease
- chordoma
- Source Database
- CIViC Evidence
- Description
- 18 advanced progressing chordoma patients entered this study (median age: 61 years; disease extent: metastatic 72% and locally advanced 28%). Epidermal growth factor receptor (EGFR) expression and activation were evaluated by immunohistochemistry and/or phospho-arrays, real-time polimerase chain reaction, fluorescence immunostaining. Six (33.3%) patients had PR and 7 (38.9%) SD, as their best Choi responses, corresponding to RECIST SD in all cases. Median PFS by Choi was 6 [interquartile (IQ) range 3-8] months. Median PFS by RECIST was 8 (IQ range 4-12) months, with a 22% CBR. This phase II study showed a modest antitumor activity of lapatinib in chordoma
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1984
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/354
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Chordoma
- Evidence Direction
- Supports
- Drug
- Lapatinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23559153
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Lapatinib | Sensitivity | true |